Jeffrey Pontius - Regencell Bioscience Independent Director
| RGC Stock | USD 5.22 0.48 10.13% |
Director
Mr. Jeffrey A. Pontius is Independent Director of Redstar Gold Corporationration Mr. Pontius has over 30 years of geological experience, and a distinguished track record of discoveries that includes four precious metal deposits in North America. Most recently, as President and CEO of International Tower Hill Mines, he led the team that discovered the Livengood Gold Deposit in Alaska, which has a current resource of over 20 million ounces of gold and continues to expand. Additionally, he led the discovery and development team for the Cripple Creek Deposit in Colorado, which is operated by AngloGold Ashanti and gold. He brings of knowledge in geology, and corporate development, and joins Redstar at an important time, with the advancement of the Newman Todd highgrade gold discovery in Red Lake and the acquisition of the district scale Shumagin project in Alaska. Mr. Pontius has an impressive history with developing and growing junior mining companies that have enhanced shareholder value. For the seven years prior to his position as President and CEO of International Tower Hill Mines, he served as the US and North American Exploration Manager for AngloGold Ashanti, was a Director of Anglo American Exploration Inc., and was a member of AngloGold Ashanti regional business development team. since 2011.
| Age | 58 |
| Tenure | 13 years |
| Address | Chinachem Leighton Plaza, Causeway Bay, Hong Kong |
| Phone | 852 2155 0823 |
| Web | https://www.regencellbioscience.com |
Regencell Bioscience Management Efficiency
The company has Return on Asset of (0.2559) % which means that on every $100 spent on assets, it lost $0.2559. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4171) %, meaning that it generated no profit with money invested by stockholders. Regencell Bioscience's management efficiency ratios could be used to measure how well Regencell Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At present, Regencell Bioscience's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.04, whereas Return On Equity is forecasted to decline to (0.14). At present, Regencell Bioscience's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.05, whereas Total Assets are forecasted to decline to about 10.8 M.Similar Executives
| Found 14 records | DIRECTOR Age | ||
| Christopher Alafi | Intracellular Th | 54 | |
| Thomas Penn | ANI Pharmaceuticals | 72 | |
| Peter Lankau | ANI Pharmaceuticals | 60 | |
| Tracy Marshbanks | ANI Pharmaceuticals | 52 | |
| Robert Nostrand | Intracellular Th | 61 | |
| Daniel Raynor | ANI Pharmaceuticals | 56 | |
| Michael Rawlins | Intracellular Th | 72 | |
| Joel Marcus | Intracellular Th | 70 | |
| Patrick Walsh | ANI Pharmaceuticals | 57 | |
| Fred Holubow | ANI Pharmaceuticals | 77 | |
| Rory Riggs | Intracellular Th | 65 | |
| Richard Lerner | Intracellular Th | 79 | |
| David Nash | ANI Pharmaceuticals | 62 | |
| Thomas Haughey | ANI Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.26 |
Regencell Bioscience Leadership Team
Elected by the shareholders, the Regencell Bioscience's board of directors comprises two types of representatives: Regencell Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regencell. The board's role is to monitor Regencell Bioscience's management team and ensure that shareholders' interests are well served. Regencell Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regencell Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jacques Vaillancourt, Executive Chairman of the Board | ||
| YiChung Chao, Special Director | ||
| YatPui Au, Chief Officer | ||
| Antonia Assang, Senior Management | ||
| Jeffrey Pontius, Independent Director | ||
| John Gray, President Director | ||
| Jack Tyrrell, Independent Director | ||
| Thomas Bell, Lead Independent Director | ||
| Wai Chung, COO Officer | ||
| Michelle Chan, Financial Controller | ||
| Charles Brymer, Independent Director | ||
| Mark Brown, CFO | ||
| Kenneth Booth, Director | ||
| Sean Keenan, Director | ||
| David Ownby, CFO, Principal Accounting Officer, Executive VP and Treasurer | ||
| Tien Chau, Executive Officer | ||
| Lee Thomas, Independent Director | ||
| Michael Campbell, Non-Executive Chairman of the Board | ||
| Robert McLeod, Director | ||
| Peter Ball, Director | ||
| Stephen Kaplan, Independent Director | ||
| Peter Brandow, Executive Vice President General Counsel | ||
| Douglas Fulcher, Independent Director | ||
| Gregory Dunn, Pres and COO | ||
| YatGai Au, Chairman Founder | ||
| Amy Miles, Chairperson and CEO | ||
| David Keyte, Independent Director | ||
| Susan Mitchell, Director | ||
| Alex Yemenidjian, Independent Director | ||
| Tim Mikula, Investor Relations | ||
| Peter Bala, President CEO, Director | ||
| George Ireland, Director | ||
| Michael McInnis, Independent Director |
Regencell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regencell Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 50.51 M | ||||
| Shares Outstanding | 13.01 M | ||||
| Shares Owned By Insiders | 88.76 % | ||||
| Shares Owned By Institutions | 0.12 % | ||||
| Number Of Shares Shorted | 3.94 K | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 4.12 X | ||||
| EBITDA | (5.5 M) |
Currently Active Assets on Macroaxis
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.